文献速递产科母胎医学

IRELAnD研究——探讨早期低剂量阿司匹林在糖尿病中的作用:一项双盲、安慰剂对照、随机试验

The IRELAnD study-investigating the role of early low-dose aspirin in diabetes mellitus: a double-blinded, placebo-controlled, randomized trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-03-08

这项在6个大学附属围产中心开展的双盲、安慰剂对照随机试验,将孕前糖尿病孕妇随机分配至每日150 mg阿司匹林组或安慰剂组(孕11至14周至36周),主要复合结局为胎盘功能障碍。阿司匹林组与安慰剂组的主要结局风险无显著差异(25% vs 21%,P=.796),但阿司匹林组整个孕期胰岛素需求量显著更低(P=.002)。

要点

  • 孕前糖尿病孕妇中,阿司匹林未降低胎盘功能障碍复合结局风险(25% vs 21%,P=.796)。
  • 阿司匹林组整个孕期胰岛素需求量显著低于安慰剂组(P=.002)。
  • 实际入组134例(阿司匹林67例、安慰剂67例),回顾性把握度为64%。

核心结论

  • 在孕前糖尿病合并妊娠中,阿司匹林未降低不良围产结局风险。
  • 与安慰剂组相比,阿司匹林组患者整个孕期所需胰岛素显著更少,提示阿司匹林对血糖控制有益。

研究设计与样本

  • 双盲、安慰剂对照随机试验,在6个大学附属围产中心开展。
  • 纳入1型或2型糖尿病病程至少6个月的孕妇,随机分配至每日150 mg阿司匹林组或安慰剂组,从孕11至14周至36周。
  • 合并糖尿病慢性血管并发症(包括慢性高血压或肾病)者被排除。
  • 计划样本量为566例,以在80%统计功效下实现主要结局降低35%;实际入组134例(阿司匹林67例、安慰剂67例),回顾性把握度为64%。

主要发现

  • 2020年2月至2022年9月期间,191例患者被判定符合条件,其中134例入组(阿司匹林67例、安慰剂67例),回顾性把握度为64%。
  • 101例(80%)为1型糖尿病,25例(20%)为2型糖尿病。
  • 治疗依从性很高且两组相似(阿司匹林组97%,安慰剂组94%)。
  • 胎盘功能障碍复合结局风险两组无差异(阿司匹林组25% vs 安慰剂组21%;P=.796)。
  • 阿司匹林组整个孕期胰岛素需求量显著低于安慰剂组:阿司匹林组从基线0.7单位/kg平均增至孕36周1.1单位/kg(患者内平均增加83%),安慰剂组从0.7单位/kg增至1.3单位/kg(患者内增加181%),同一孕周期间比较P=.002。

局限性

  • 未达到目标样本量,受COVID-19疫情影响。
  • 实际入组134例,回顾性把握度为64%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although aspirin therapy is being increasingly advocated with the intention of risk modification for a wide range of pregnancy complications, women with prepregnancy diabetes mellitus are commonly excluded from clinical trials. OBJECTIVE: The primary aim of this study was to examine the effect of aspirin therapy on a composite measure of adverse perinatal outcome in pregnancies complicated by pregestational diabetes mellitus. STUDY DESIGN: A double-blinded, placebo-controlled randomized trial was conducted at 6 university-affiliated perinatology centers. Women with type 1 diabetes mellitus or type 2 diabetes mellitus of at least 6 months' duration were randomly allocated to 150-mg daily aspirin or placebo from 11 to 14 weeks' gestation until 36 weeks. Established vascular complications of diabetes mellitus, including chronic hypertension or nephropathy, led to exclusion from the trial. The primary outcome was a composite measure of placental dysfunction (preeclampsia, fetal growth restriction, preterm birth <34 weeks' gestation, or perinatal mortality). The planned sample size was 566 participants to achieve a 35% reduction in the primary outcome, assuming 80% statistical power. Secondary end points included maternal and neonatal outcomes and determination of insulin requirements across gestation. Data were centrally managed using ClinInfo and analyzed using SAS 9.4. The 2 treatment groups were compared using t tests or chi-square tests, as required, and longitudinal data were compared using a repeated-measures analysis. RESULTS: From February 2020 to September 2022, 191 patients were deemed eligible, 134 of whom were enrolled (67 randomized to aspirin and 67 to placebo) with a retrospective power of 64%. A total of 101 (80%) women had type 1 diabetes mellitus and 25 (20%) had type 2 diabetes mellitus. Reaching the target sample size was limited by the impact of the COVID-19 pandemic. Baseline characteristics were similar between the aspirin and placebo groups. Treatment compliance was very high and similar between groups (97% for aspirin, 94% for placebo). The risk of the composite measure of placental dysfunction did not differ between groups (25% aspirin vs 21% placebo; P=.796). Women in the aspirin group had significantly lower insulin requirements throughout pregnancy compared with the placebo group. Insulin requirements in the aspirin group increased on average from 0.7 units/kg at baseline to 1.1 units/kg by 36 weeks' gestation (an average 83% within-patient increase), and increased from 0.7 units/kg to 1.3 units/kg (a 181% within-patient increase) in the placebo group, over the same gestational period (P=.002). Serial hemoglobin A1c levels were lower in the aspirin group than in the placebo group, although this trend did not reach statistical significance. CONCLUSION: In this multicenter, double-blinded, placebo-controlled randomized trial, aspirin did not reduce the risk of adverse perinatal outcome in pregnancies complicated by prepregnancy diabetes mellitus. Compared with the placebo group, aspirin-treated patients required significantly less insulin throughout pregnancy, indicating a beneficial effect of aspirin on glycemic control. Aspirin may exert a plausible placenta-mediated effect on pregestational diabetes mellitus that is not limited to its antithrombotic properties.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Finnegan C, Dicker P, Asandei D, et al. The IRELAnD study-investigating the role of early low-dose aspirin in diabetes mellitus: a double-blinded, placebo-controlled, randomized trial. Am J Obstet Gynecol MFM. 2024. PMID: 38461094. doi:10.1016/j.ajogmf.2024.101297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。